Trial Protocol for Pain Relief in Diabetic Neuropathy with Insulin Pumps
Painful diabetic neuropathy (PDN) is a prevalent complication of diabetes that significantly impacts patients' quality of life. Emerging research indicates that glycaemic variability may be associated with fluctuations in pain intensity, suggesting that managing these fluctuations could alleviate symptoms. The PAINLESS study is designed to explore this hypothesis by evaluating the effects of hybrid closed loop (HCL) insulin delivery systems on pain intensity in individuals suffering from PDN.
This two-centre, randomized crossover trial will recruit 49 adults with type 1 diabetes and PDN. Participants will undergo two 12-week intervention periods in a randomized sequence: one period will involve standard care that includes continuous glucose monitoring (CGM), while the other will utilize HCL therapy with the Tandem t:slim X2 insulin pump equipped with Control-IQ technology. The primary outcome of the study is the change in 7-day average 24-hour pain intensity, measured on a numerical rating scale from 0 to 10, recorded in daily pain diaries.
Secondary outcomes will encompass various metrics, including pain trajectory and durability, functional and quality of life assessments, mood evaluations, and health status indicators. Exploratory endpoints will incorporate neurophysiological assessments and data from activity and sleep trackers. The study will employ an intention-to-treat analysis and mixed effect models to ensure robust statistical evaluations.
The trial is expected to span 24 months, with 18 months dedicated to recruitment and follow-up, and an additional 6 months for close-out and dissemination of results. The first participant was recruited on March 27, 2026, and the study aims to complete enrollment by February 9, 2027. Participants will be drawn from specialized PDN clinics and will continue their usual neuropathic pain medications during the trial, allowing for minor adjustments under clinical supervision.
The findings from this study could provide valuable insights into the efficacy of HCL systems in managing pain associated with diabetic neuropathy, potentially addressing a significant unmet clinical need in diabetes care.




